Filing Flows › Niagen Bioscience (NAGE) › Q1 2026
Niagen Bioscience (NAGE) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 6, 2026
Niagen Bioscience (NAGE) reported revenue of $31.5M for the first quarter 2026 (Q1 2026), +3% from a year earlier and -7% from the quarter before. Operating margin was 5.0%, net earnings $6.3M (20.1% of revenue).
Niagen Bioscience, Q1 2026: revenue $31.5M (+3% year over year), operating margin 5.0%, net earnings $6.3M, operating cash flow −$1.2M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $31.5M | -7% | +3% |
| Gross profit | $20.0M | -8% | +3% |
| Operating profit | $1.6M | -61% | -67% |
| Net earnings | $6.3M | +53% | +25% |
| Operating cash flow | −$1.2M | -276% | -115% |
What changed
Revenue was $31.5M in Q1 2026, up 3% year over year and down 7% from the previous quarter. Consumer Products segment was the largest line at 71% of revenue. Consumer Products segment added $912K year over year (up 4%), 92% of the total change. Analytical Reference Standards and Services segment declined 48%.
Gross margin was 63.5%, unchanged from Q1 2025. Operating profit was $1.6M, a 5.0% margin (down 10.6 points year over year). Operating profit fell $3.2M even though revenue rose $1.0M versus Q1 2025, so costs grew faster than sales. Operating expenses grew 26% against revenue growth of 3%. The fastest-growing cost line was General & admin (+40%). Net earnings were $6.3M, up 25% year over year. The effective tax rate was 6.2%. Non-operating items added $5.2M, 77% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$1.2M. Non-cash charges added back $291K of depreciation and amortization and $1.7M of share-based compensation. Working capital and other items used $9.5M.
Questions
What was Niagen Bioscience's revenue in the first quarter 2026?
Niagen Bioscience (NAGE) reported revenue of $31.5M for the first quarter 2026 (Q1 2026), +3% from a year earlier and -7% from the quarter before.
Was Niagen Bioscience profitable in the first quarter 2026?
Operating profit was $1.6M (5.0% of revenue) and net earnings $6.3M.
Source: Niagen Bioscience 10-Q on SEC EDGAR.